Argá Medtech secures EUR 54 million towards its atrial fibrillation treatment

Argá Medtech, a pioneer in pulsed field ablation technology, has successfully completed its EUR 54 million Series B financing round.

Headquartered at the Biopôle life sciences campus in Lausanne, with additional operations in San Diego, California, Argá Medtech is at the forefront of developing next-generation treatments for cardiac arrhythmias, specifically atrial fibrillation (AF). The company’s Coherent Sine-Burst Electroporation™ (CSE™) technology represents a significant advancement in the field of minimally invasive surgical interventions for treating AF.

Argá Medtech’s novel CSE™ ablation system offers electrophysiologists an unparalleled capability to safely and efficiently treat various regions of the heart using a versatile, all-in-one catheter. This technology not only ensures a safer treatment method by minimizing the risk of thermal injuries to surrounding tissues but also simplifies the procedure, reducing the overall treatment time and associated costs.

The company recently announced the successful closure of a EUR 54 million Series B funding round. This significant financial milestone, led by a consortium of investors including Advent Life Sciences (UK), Earlybird Health (Germany), Gilde Healthcare (the Netherlands), and an undisclosed strategic investor, aims to propel the clinical studies of Argá Medtech’s innovative cardiac ablation system in both the United States and the European Union.

David Neale, CEO of Argá Medtech, expressed his gratitude for the investors’ support, highlighting their shared vision of revolutionizing AF ablation treatment. The funds will primarily facilitate the execution of an Investigational Device Exemption (IDE) study in the US and a CE Mark study in the EU, paving the way for broader accessibility of their CSE™ Pulsed Field Ablation (PFA) system.

A safer, more precise alternative for stroke patients

The funding also supports the expansion of Argá Medtech’s operations in San Diego, anticipating the increase in clinical activities in the United States. Furthermore, this Series B round builds on the company’s momentum following a 48-patient first-in-human study in Europe, which showcased the platform’s efficacy in treating AF.

Atrial fibrillation, as the most common cardiac arrhythmia globally, significantly increases the risk of stroke among patients. The traditional thermal energy ablation methods, while effective, carry higher risks compared to PFA energy delivery. Argá Medtech’s solution aims to provide a safer, more precise alternative for the millions affected by this condition.